Publications scientifiques

Une forte valorisation scientifique de nos études attestée par nos publications

Effects of short- and long-acting beta-agonists on asthma exacerbations: a prospective cohort

Van Ganse E, Texier N, Dima AL, Belhassen M, Laforest L, Herbage S, Schück S, Hernandez G, Garin O, Ferrer M, de Bruin M; ASTRO-LAB group

Ann Allergy Asthma Immunol. 2020 Mar;124(3):254-260

Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment

Scotte F, Simon H, Laplaige P, Antoine EC, Spasojevic C, Texier N, Gouhier K, Chouaid C

BMJ Support Palliat Care. 2021 Oct;27

Validation of a videoconference-based neuropsychological assessment: The e-COG study

Gnassounou R, Défontaines B, Denolle S, Brun S, Schück S, Germain R, Schwartz D, Cacciamani F, Michon A, Belin C, Mailler D.

Alzheimer’s Dement 2020 ; 16: e047330

Cohorte EMMY : Données de survie hors essai clinique en stades avancés de myélome multiple

C. Hulin, M. Macro, L. Frenzel, B. Royer, K. Belhadj, A. Perrot, D. Caillot, X. Leleu, A. Farge, A. Vekhoff, S. Schulmann, R. Garlantezec, N. Texier, R. Germain, C. Nobili Escriva, C. Boccaccio, O. Decaux

41 ème Congrès de la société française d’hématologie, 2021, Paris. Communication orale

Etude EmmY : Caractéristiques des patients atteints de myélome multiple et prise en charge thérapeutique en première ligne en vie réelle en France

Decaux, L. Frenzel, R. Garlantezec, M. Macro, K. Belhadj, A. Perrot, R. Germain, N. Texier, M. Willaime, C. Nobili Escriva, C. Boccaccio, C. Hulin

Congrès de la société française d’hématologie, 2020, Paris. Communication orale

Randomised, double-blind, placebo-controlled trial of glycopyrronium in children and adolescents with severe sialorrhoea and neurodisabilities: protocol of the SALIVA trial

Fayoux P, Dinomais M, Shaw H, Probert N, Villain F, Pouchain D, Texier N, Auvin S

BMJ Paediatr Open. 2023 May;7

Does Gender Influence Adherence to Inhaled Therapy in COPD? An Observational Study of Patients Treated with Indacaterol/Glycopyrronium 110/50 ug o.d. (IND/GLY)

C. Raherison, L. Decuypere, M. Pouriel, N. Roche

American Thoracic Society, 2019

Comment améliorer l’acceptabilité vaccinale (évaluation, pharmacovigilance, communication, santé publique, obligation vaccinale, peurs et croyances).

Dutilleul A, Morel J, Schilte C, Launay O; les participants à la table ronde « Sujet d’actualité (1) » des Ateliers de Giens XXXIV.

Therapie. 2019 Feb;74(1):119-129.

Compliance with national guidelines for antibiotic prophylaxis prescription with a surgical abortion: Results of the Mya study.

Hamdaoui N, David P, Rondeau V, Pouriel M, Agostini A.

J Gynecol Obstet Hum Reprod. 2019 May;48(5):315-317.

EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.

Hernandez G, Garin O, Dima AL, Pont A, Martí Pastor M, Alonso J, Van Ganse E, Laforest L, de Bruin M, Mayoral K, Serra-Sutton V, Ferrer M; ASTRO-LAB Group.

J Med Internet Res. 2019 Jan 23;21(1):e10178.

How to improve vaccine acceptability (evaluation, pharmacovigilance, communication, public health, mandatory vaccination, fears and beliefs).

Dutilleul A, Morel J, Schilte C, Launay O; participants of Giens XXXIV Round Table “hot topic No. 1”.

Therapie. 2019 Feb;74(1):131-140.

Observational study of adherence to indacaterol/glycopyrronium 110/50µg o.d. (IND/GLY) in COPD

N. Roche, Le Gros V, M. Pouriel, L. Decuypere, C. Raherison

ERS International Congress 2018 – sept 2018

Defining the « Frequent Exacerbator » Phenotype in COPD: A Hypothesis-Free Approach.

Le Rouzic O, Roche N, Cortot AB, Tillie-Leblond I, Masure F, Perez T, Boucot I, Hamouti L, Ostinelli J, Pribil C, Poutchnine C, Schück S, Pouriel M, Housset B.

Chest. 2018 May;153(5):1106-1115.

Explaining the Amount and Consistency of Medical Care and Self-Management Support in Asthma: A Survey of Primary Care Providers in France and the United Kingdom.

de Bruin M, Dima AL, Texier N, van Ganse E; ASTRO-LAB group.

J Allergy Clin Immunol Pract. 2018 Nov-Dec;6(6):1916-1925.e7.

Assessment of the safety of long-acting β2-agonists in routine asthma care: the ASTRO-LAB protocol.

Van Ganse E, Texier N, Dima AL, Laforest L, Ferrer M, Hernandez G, Schuck S, Herbage S, Vial D, de Bruin M; ASTRO-LAB group.

NPJ Prim Care Respir Med. 2015 Jun 18;25:15040.